How we help Biotechs save lives sooner
Patients with rare diseases face all kinds of challenges in their lives, including accessing the most up to date treatments. A serious health condition is hard enough, without compounding it with uncertainty around medication. Biotech innovation is constantly exploring new solutions, but connecting them – all of them – is a highly complex job in itself. At BAP Pharma, our mission is deeply rooted in bridging the critical gap between patients with rare diseases and potentially life-saving investigational drugs. We do this by working closely with those at both ends of the journey: the patient support groups who have the networks and the biotechs whose investigational therapies have the potential to make a big difference. It’s a journey fraught with maybes. But our understanding of the complexities inherent in drug development and commercialisation allows us to give biotech companies – especially those with focused pipelines – clear, flexible pathways while also ensuring vital access to patients in urgent need. Creating a much greater level of certainty at every stage. Here we outline how a partnership with BAP Pharma works, for Biotech’s and the patients hoping for help at the other end of the funnel.
What do biotech companies get out of a strategic partnership with BAP Pharma?
Phase 2 and Phase 3 clinical trials are pivotal to Biotech companies – they are the essential blueprint for getting medicines to market. To be effective they require strict inclusion criteria, which – inevitably – ensures that large numbers of patients won’t tick all the boxes. Being ineligible, on the wrong side of that threshold, can mean facing a dire reality – having no treatment options. The potential benefits an investigational therapy could offer are so close and yet so far. Which is where we come in. By engaging with BAP Pharma, biotech companies can gain two key advantages.
- The first is a partner committed to expanded access to your investigational drugs in order to save more lives and increase the potential outcomes.
- The second is a partner who can strategically mitigate the risks that come with regulatory complexities and global distribution.
Because we understand so much about both ends of the process, and the pressures on those involved, we can ensure that patients across the globe can benefit from promising therapies, even before commercial availability, wherever in the world they are. This is particularly crucial for those excluded from clinical trials, requiring continued access post-trial, or needing drugs not pursued for marketing authorisation in their region. In what can be a highly unpredictable landscape, our teams can proactively address all the different challenges and create greater certainty.
What does ‘certainty’ look like?
We provide this certainty to all kinds of partners, from global pharma leaders to Biotech innovators of all sizes. But we can be so much more than just a partner. We always aspire to be a strategic ally who can help you confidently streamline your pathways to success, whatever they are. So we can both ensure that your drug reaches more of the patients who need it most, with certainty built in. To speak to our Medicines Access team, get in touch with them here.
A mid-sized biotech sponsor was preparing a Phase III oncology study across six European markets.
The trial required multi-language labelling aligned to local regulatory requirements, blind packaging with strict protocol adherence, and rapid timelines to meet site activation milestones. As the study progressed, risk began to build.
Late-stage protocol amendments introduced ongoing changes to labelling requirements. At the same time, increasing translation complexity created additional pressure on regulatory alignment, while compressed timelines heightened the risk of version control errors.
Issues were not theoretical concerns. They represented real operational and regulatory exposure, where a minor packaging discrepancy could delay site activation, trigger relabelling campaigns, increase regulatory scrutiny, or disrupt patient dosing.
The sponsor needed a partner who could reduce risk without slowing delivery or increasing operational complexity.
